Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Acerta Pharma BV

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.